Oxalic Acid

Oxalic Acid

SCHEMBL3973877

CC(C)C.CC(C)C.O=C(O)C(=O)O.O=C(O)C(=O)O

nearest known ligand 0.54

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

OPRM1SLC6A4

The experimentally established mechanism targets of Oxalic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
TP53 P04637 1/20 0.50
FFAR3 O14843 2/20 0.42
LCK P06239 1/20 0.42
FYN P06241 1/20 0.42
SLC7A5 Q01650 1/20 0.39
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
CA9 Q16790 1/20 0.36
LDHA P00338 1/20 0.36
LDHB P07195 1/20 0.36
CYP2D6 P10635 1/20 0.35
CYP2C19 P33261 1/20 0.35
RNPEP Q9H4A4 1/20 0.33
ALDH1A1 P00352 1/20 0.33
TDP1 Q9NUW8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Oxalic Acid SCHEMBL28595430 0.86 TP53 (0.57) TP53FFAR3LCKFYNSLC7A5
Oxalic Acid SCHEMBL890984 0.86 TP53 (0.57) TP53FFAR3LCKFYNSLC7A5
Isobutane SCHEMBL28410846 0.84 CA1 (0.56) TP53FFAR3LCKFYNSLC7A5
Isobutane SCHEMBL5453 0.84 CA1 (0.56) TP53FFAR3LCKFYNSLC7A5
Isobutane SCHEMBL1580573 0.84
Isobutane SCHEMBL132611 0.84 CA1 (0.56) TP53FFAR3LCKFYNSLC7A5
Isobutane SCHEMBL43551 0.84 CA1 (0.56) TP53FFAR3LCKFYNSLC7A5
Isobutane SCHEMBL6337855 0.84 CA1 (0.56) TP53FFAR3LCKFYNSLC7A5
Isobutane SCHEMBL28694060 0.84 CA1 (0.56) TP53FFAR3LCKFYNSLC7A5
Isobutane SCHEMBL13372605 0.84 CA1 (0.56) TP53FFAR3LCKFYNSLC7A5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1874301-A4 NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT MERCK & CO INC (US) 2009-05-06 EP disclosed
US-20090054423-A1 Niacin receptor agonists, compositions containing such compounds and methods of treatment MERCK SHARP & DOHME CORP. 2009-02-26 US disclosed
EP-1874301-A1 NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT Merck & Co., Inc. (US) 2008-01-09 EP disclosed
WO-2006113150-A1 NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT MERCK & CO., INC. (US) 2006-10-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054423-A1 Niacin receptor agonists, compositions containing such compounds and methods of treatment FFAR1, HCAR1, GPR119 TP53 3605/4885FFAR3 7/4885LCK 4492/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.